Advertisement

Archives of Gynecology and Obstetrics

, Volume 284, Issue 1, pp 209–214 | Cite as

Human papilloma virus persistence and neopterin, folate and homocysteine levels in cervical dysplasias

  • Faruk Abike
  • Ayse Basak Engin
  • İlkkan Dunder
  • Omer Lutfi Tapisiz
  • Canan Aslan
  • Lale Kutluay
Gynecologic Oncology

Abstract

Objective

To investigate the relationship between human papilloma virus (HPV) infection persistence and serum folate, vitamin B12, homocysteine, neopterin levels in cervical dysplasia.

Study design

Through the years 2007–2008, 122 women who have admitted to Gynecology Clinic were evaluated for cervical cytology, demographical characteristics, HPV infection, serum folate, vitamin B12, homocysteine, albumin, and neopterin levels.

Results

Considering all the cases, the highest percentage of the HPV-infected patients was in high-grade squamous intraepithelial lesion (HSIL) group (83%, n = 25). The serum folate levels in all patient groups [HSIL 10.0 ± 0.4 ng/ml, low-grade squamous intraepithelial lesion (LSIL) 10.6 ± 0.5 ng/ml, atypical squamous cells-undetermined significance (ASCUS) 11.1 ± 0.8 ng/ml] were lower than control group (11.9 ± 0.5 ng/ml; p < 0.05). The vitamin B12 levels were not significantly altered in any of the patient groups. The serum homocysteine levels in all patient groups (HSIL 10.4 ± 0.5 Umol/l, LSIL 10.1 ± 0.5 Umol/l, ASCUS 10.5 ± 0.7 Umol/l) were higher than the control group (7.9 ± 0.5 Umol/l; p < 0.05). The neopterin levels of HSIL group (1.0 ± 0.2 ng/ml) were lower than the control group (1.5 ± 0.2 ng/ml; p < 0.05). The serum neopterin concentrations of HSIL with HPV group (0.6 ± 0.1 ng/ml) were significantly lower than HSIL without HPV (2.4 ± 0.9 ng/ml) and other study groups (p < 0.05). The serum homocysteine levels of HSIL HPV(+) group and LSIL HPV(+) were higher than control group (p < 0.05). The serum albumin levels of HSIL with HPV group are lower than control and other groups (p < 0.05). In all cervical dysplasia groups, folate levels in patients infected with HPV are lower than in HPV(−) patients (p < 0.05).

Conclusions

Folic acid deficiency could be caused by insufficient cellular immunity. In case of folate deficiency, the predisposition of HPV infection persistency and progression of cervical dysplasia increase. The fact that neopterin is a strong cellular immunity marker and it was detected in patients with HPV persistence and cervical dysplasia in lower levels shows that these patients may have relatively insufficient immune system. In order for dysplasia progression to be prevented, folate fortification on diets may be advised to HPV-infected women.

Keywords

HPV infection Cervical dysplasia Folate Homocysteine Neopterin 

Notes

Conflict of interest

None.

References

  1. 1.
    Ferlay J, Bray F, Pisani P, Parkin DM (2001) GLOBOCAN 2000: cancer incidence, mortality and prevalence worldwide, version 1.0. IARC Press, LyonGoogle Scholar
  2. 2.
    Parkin DM, Bray FI, Devesa SS (2001) Cancer burden in the year 2000. The global picture. Eur J Cancer 37(Suppl 8):S4–S66PubMedCrossRefGoogle Scholar
  3. 3.
    Carter JJ, Koutsky LA, Hughes JP, Lee SK, Kuypers J, Kiviat N et al (2000) Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis 181:1911–1919PubMedCrossRefGoogle Scholar
  4. 4.
    Bosch FX, Lorincz A, Munoz N et al (2002) The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 55:244–265PubMedCrossRefGoogle Scholar
  5. 5.
    Chew GK, Cruickshank ME, Rooney PH, Miller ID, Parkin DE, Murray GI (2005) Human papillomavirus 16 infection in adenocarcinoma of the cervix. Br J Cancer 93:1301–1304PubMedCrossRefGoogle Scholar
  6. 6.
    (2006) IARC monographs on the evaluation of carcinogenic risks to humans, volume 90, human papilloma viruses. International Agency for Research on Cancer, LyonGoogle Scholar
  7. 7.
    Schiffman M, Castle PE (2003) Human papillomavirus: epidemiology and public health. Arch Pathol Lab Med 127(8):930–934PubMedGoogle Scholar
  8. 8.
    ASCUS-LSIL Traige Study (ALTS) Group (2003) A randomized trial on the management of low-grade squamous intraepithelial lesion cytology interpretations. Am J Obstet Gynecol 188(6):1393–1400Google Scholar
  9. 9.
    Whitehead N, Reyner F, Lindenbaum J (1973) Megaloblastic changes in the cervical epithelium. J Am Med Assoc 226:1421–1424CrossRefGoogle Scholar
  10. 10.
    Butterworth CE (1992) Effect of folate on cervical cancer. Ann N Y Acad Sci 669:293–299PubMedCrossRefGoogle Scholar
  11. 11.
    Mason JB, Levesque T (1996) Folate: effects on carcinogenesis and the potential for cancer chemoprevention. Oncology (Basel) 10:1727–1742Google Scholar
  12. 12.
    Weir DG, Scott JM (1999) Cobalamins: physiology, dietary sources and requirements. In: Sadler MJ, Strain JJ, Caballero B (eds) Encyclopedia of human nutrition. Academic Press, London, pp 394–401Google Scholar
  13. 13.
    McPartlin J, Weir DG, Scott JM (1999) Folic acid: physiology, dietary sources and requirements. In: Sadler MJ, Strain JJ, Caballero B (eds) Encyclopedia of human nutrition. Academic Press, London, pp 803–811Google Scholar
  14. 14.
    Flynn MA, Herbert V, Nolph GB, Krause G (1997) Atherogenesis and the homocysteine–folate–cobalamin triad: do we need standardized analyses? J Am Coll Nutr 16:258–267PubMedGoogle Scholar
  15. 15.
    Savage DG, Lindenbaum J, Stabler SP, Allen RH (1994) Sensitivity of serum methylmalonic acid, total homocysteine determinations for diagnosing cobalamin, folate deficiencies. Am J Med 96(3):239–246PubMedCrossRefGoogle Scholar
  16. 16.
    Weinstein SJ, Ziegler RG, Selhub J, Fears TR, Strickler HD, Brinton LA, Hamman RF, Levine RS, Mallin K, Stolley PD (2001) Elevated serum homocysteine levels and increased risk of invasive cervical cancer in US women. Cancer Causes Control 12(4):317–324PubMedCrossRefGoogle Scholar
  17. 17.
    Kwaśniewska A, Tukendorf A, Goździcka-Józefiak A, Semczuk-Sikora A, Korobowicz E (2002) Content of folic acid and free homocysteine in blood serum of human papillomavirus-infected women with cervical dysplasia. Eur J Gynaecol Oncol 23(4):311–316PubMedGoogle Scholar
  18. 18.
    Wachter H, Fuchs D, Hausen A, Reibnegger G, Weiss C, Werner R, Werner-Febmayer C (1992) Neopterin: biochemistry, methods, clinical applications. Walter de Gruyter, New YorkCrossRefGoogle Scholar
  19. 19.
    Reibnegger CJ, Bichler AH, Dapunt O, Fuchs DN, Fuith LC, Hausen A, Hetzeb HM, Lutz H, Werner ER, Wachter H (1986) Neopterin as a prognostic indicator in patients with carcinoma of the uterine cervix. Cancer Res 46:950–955PubMedGoogle Scholar
  20. 20.
    Fuchs D, Weiss G, Reibnegger G, Wachter H (1992) The role of neopterin as a monitor of cellular immune activation in transplantation, inflammatory, infectious, and malignant diseases. Crit Rev Clin Lab Sci 29(3–4):307–341PubMedCrossRefGoogle Scholar
  21. 21.
    Polterauer S, Grimm C, Tempfer C, Sliutz G, Speiser P, Reinthaller A, Hefler LA (2007) C-reactive protein is a prognostic parameter in patients with cervical cancer. Gynecol Oncol 107(1):114–117PubMedCrossRefGoogle Scholar
  22. 22.
    Yamada N, Nakayama A, Kubota K, Kawakami A, Suzuki E (2008) Structure and function changes of oxidized human serum albumin: physiological significance of the biomarker and importance of sampling conditions for accurate measurement. Rinsho Byori 56(5):409–415PubMedGoogle Scholar
  23. 23.
    Chandra S, Chandra RK (1986) Nutrition, immune response, and outcome. Prog Food Nutr Sci 10:1–65PubMedGoogle Scholar
  24. 24.
    Dhur A, Galan P, Hercberg S (1991) Folate status and the immune system. Prog Food Nutr Sci 15:43–60PubMedGoogle Scholar
  25. 25.
    Wilke CM, Hall BK, Hoge A, Paradee W, Smith DI, Glover TW (1996) FRA3B extends over a broad region and contains a spontaneous HPV 16 integration site: direct evidence for the coincidence of viral integration sites and fragile sites. Hum Mol Genet 5:187–195PubMedCrossRefGoogle Scholar
  26. 26.
    Popescu NC, DiPaolo JA, Amsbaugh SC (1987) Integration sites of human papillomavirus 18 DNA sequences on HeLa cell chromosomes. Cytogenet Cell Genet 44:58–62PubMedCrossRefGoogle Scholar
  27. 27.
    Piyathilake CJ, Henao OL, Meleth S, Partridge E, Heimburger D (2003) Folate is associated with the acquisition, persistence and clearance of high-risk (HR) human papillomavirus (HPV). FASEB J 17:A373Google Scholar
  28. 28.
    Piyathilake CJ, Henao OL, Macaluso M, Cornwell PE, Meleth S, Heimburger DC et al (2004) Folate is associated with the natural history of high-risk human papillomaviruses. Cancer Res 64:8788–8793PubMedCrossRefGoogle Scholar
  29. 29.
    Piyathilake CJ, Macaluso M, Brill I, Heimburger DC, Partridge EE (2007) Lower red blood cell folate enhances the HPV-16-associated risk of cervical intraepithelial neoplasia. Nutrition 23(3):203–210PubMedCrossRefGoogle Scholar
  30. 30.
    Kwaśniewska A, Tukendorf A, Semczuk M (1997) Folate deficiency and cervical intraepithelial neoplasia. Eur J Gynaecol Oncol 18(6):526–530PubMedGoogle Scholar
  31. 31.
    Piyathilake CJ, Henao OL, Macaluso M, Cornwell PE, Meleth S, Heimburger DC, Partridge EE (2004) Folate is associated with the natural history of high-risk human papillomaviruses. Cancer Res 64(23):8788–8793PubMedCrossRefGoogle Scholar
  32. 32.
    Schroecksnadel K, Frick B, Fiegl M, Winkler C, Denz HA, Fuchs D (2007) Hyperhomocysteinaemia and immune activation in patients with cancer. Clin Chem Lab Med 45(1):47–53PubMedCrossRefGoogle Scholar
  33. 33.
    Oner N, Vatansever U, Karasalihoğlu S, Ekuklu G, Celtik C, Biner B (2006) The prevalence of folic acid deficiency among adolescent girls living in Edirne, Turkey. J Adolesc Health 38(5):599–606PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Faruk Abike
    • 1
  • Ayse Basak Engin
    • 2
  • İlkkan Dunder
    • 3
  • Omer Lutfi Tapisiz
    • 4
  • Canan Aslan
    • 5
  • Lale Kutluay
    • 6
  1. 1.Department of Gynecological OncologyBayindir HospitalAnkaraTurkey
  2. 2.Department of Toxicology, Faculty of PharmacyGazi UniversityAnkaraTurkey
  3. 3.Department of Gynecological Oncology, Faculty of MedicineBilim UniversityIstanbulTurkey
  4. 4.Dr Zekai Tahir Burak Women Health and Research HospitalAnkaraTurkey
  5. 5.Institute of Health SciencesBilim UniversityIstanbulTurkey
  6. 6.Department of PathologyBayindir HospitalAnkaraTurkey

Personalised recommendations